Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival

Circulation: Heart Failure

Volumn 9, Issue 7, 2016, Pages

  Florea, Viorel G ^a,c   Rector, Thomas S ^b,c   Anand, Inder S ^a   Cohn, Jay N ^c  

^a VA MEDICAL CENTER   (United States)

^b Minneapolis Veterans Affairs Health Care System   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

biomarker; blood pressure; heart failure; prognosis; valsartan

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; ENDOTHELIN; GALECTIN 3; GROWTH DIFFERENTIATION FACTOR 15; HIGH SENSITIVITY C REACTIVE PROTEIN; HIGH SENSITIVITY TROPONIN T; NORADRENALIN; RENIN; SOLUBLE ST2; TROPONIN T; UNCLASSIFIED DRUG; VALSARTAN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINERALOCORTICOID ANTAGONIST;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART FAILURE WITH IMPROVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; POST HOC ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; AGED; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONVALESCENCE; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MULTICENTER STUDY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RECOVERY OF FUNCTION; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VALSARTAN; VENTRICULAR FUNCTION, LEFT;

EID: 84979000418     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003123     Document Type: Article

References (23)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013 128 1810 1852. doi: 10.1161/CIR.0b013e31829e8807
2. Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS, Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 2011 17 527 532. doi: 10.1016/j.cardfail.2011.03.005
3. Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC, Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 2014 129 2380 2387. doi: 10.1161/CIRCULATIONAHA.113.006855
4. Joyce E, Chung C, Badloe S, Odutayo K, Desai A, Givertz MM, Nohria A, Lakdawala NK, Stewart GC, Young M, Weintraub J, Stevenson LW, Lewis EF, Variable Contribution of Heart Failure to Quality of Life in Ambulatory Heart Failure With Reduced, Better, or Preserved Ejection Fraction. JACC Heart Fail 2016 4 184 193. doi: 10.1016/j.jchf.2015.12.011
5. Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 345 1667 1675. doi: 10.1056/NEJMoa010713
6. Wong M, Staszewsky L, Latini R, Barlera S, Glazer R, Aknay N, Hester A, Anand I, Cohn JN, Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data. J Am Coll Cardiol 2004 43 2022 2027. doi: 10.1016/j.jacc.2003.12.053
7. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005 18 1440 1463. doi: 10.1016/j.echo.2005.10.005
8. Wong M, Staszewsky L, Volpi A, Latini R, Barlera S, Höglund C, Quality assessment and quality control of echocardiographic performance in a large multicenter international study: Valsartan in heart failure trial (Val-HeFT). J Am Soc Echocardiogr 2002 15 293 301
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 1999 130 461 470
10. Masson S, Latini R, Anand IS, Vago T, Angelici L, Barlera S, Missov ED, Clerico A, Tognoni G, Cohn JN, Direct comparison of B-Type natriuretic peptide (BNP) and amino-Terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data. Clin Chem 2006 52 1528 1538
11. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN, Val-HeFT Investigators Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003 107 1278 1283
12. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN, Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 2007 116 1242 1249
13. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN, Val-HeFT Investigators C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 2005 112 1428 1434. doi: 10.1161/CIRCULATIONAHA.104.508465
14. Anand IS, Rector TS, Kuskowski M, Adourian A, Muntendam P, Cohn JN, Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013 15 511 518. doi: 10.1093/eurjhf/hfs205
15. Anand IS, Rector TS, Kuskowski M, Snider J, Cohn JN, Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail 2014 7 418 426. doi: 10.1161/CIRCHEARTFAILURE.113.001036
16. Anand IS, Kempf T, Rector TS, Tapken H, Allhoff T, Jantzen F, Kuskowski M, Cohn JN, Drexler H, Wollert KC, Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation 2010 122 1387 1395. doi: 10.1161/CIRCULATIONAHA.109.928846
17. de Groote P, Fertin M, Duva Pentiah A, Goéminne C, Lamblin N, Bauters C, Long-Term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after β-blocker therapy. Circ Heart Fail 2014 7 434 439. doi: 10.1161/CIRCHEARTFAILURE.113.000813
18. Cintron G, Johnson G, Francis G, Cobb F, Cohn JN, Prognostic significance of serial changes in left ventricular ejection fraction in patients with congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation 1993 87 VI17 VI23
19. Greenberg B, Quinones MA, Koilpillai C, Limacher M, Shindler D, Benedict C, Shelton B, Effects of long-Term enalapril therapy on cardiac structure and function in patients with left ventricular dysfunction. Results of the SOLVD echocardiography substudy. Circulation 1995 91 2573 2581
20. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N, Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997 29 1060 1066
21. Groenning BA, Nilsson JC, Sondergaard L, Fritz-Hansen T, Larsson HB, Hildebrandt PR, Antiremodeling effects on the left ventricle during beta-blockade with metoprolol in the treatment of chronic heart failure. J Am Coll Cardiol 2000 36 2072 2080
22. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M, Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-Treated black population with heart failure: results from A-HeFT. J Card Fail 2007 13 331 339
23. Stevenson LW, Heart failure with better ejection fraction: a modern diagnosis. Circulation 2014 129 2364 2367